All In Biotech

Investigational drug · Phase 2

Evalstotug

Also called: BA3071

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck.

Phase 2

Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

1

Any phase or sponsor naming "Evalstotug"

First trial start

2022

Dec 13, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Evalstotug", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Head and Neck Cancer
  • Squamous Cell Carcinoma of Head and Neck
  • Recurrent Squamous Cell Carcinoma of the Head and Neck
  • Metastatic Cancer
  • Metastatic Squamous Cell Carcinoma of the Head and Neck

Approved drugs for the same conditions: Head and neck cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Evalstotug" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Head and Neck Cancer

  • APG-157Phase 33 trials

    Aveta Biomics, Inc. · Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of the Oropharynx

  • SurzebiclimabBGB-A425Phase 33 trials

    BeOne Medicines (BeiGene) · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion

  • Buparlisib & PaclitaxelAN2025Phase 31 trial

    Adlai Nortye Biopharma Co., Ltd. · Head and Neck Cancer

  • EvorpaceptALX148Phase 25 trials

    ALX Oncology Inc. · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Metastatic

  • BT5528nuzefatide pevedotinPhase 23 trials

    BicycleTx Limited · Advanced Solid Tumors, Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer

  • INCAGN02385Phase 23 trials

    Incyte · Melanoma, Endometrial Cancer, Head and Neck Cancer

  • INCAGN02390Phase 23 trials

    Incyte · Melanoma, Endometrial Cancer, Head and Neck Cancer

  • MCLA-129Phase 23 trials

    Betta Pharmaceuticals Co., Ltd. · Non-Small Cell Lung Cancer, Solid Tumor, Head and Neck Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.